ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-09-20 17:12 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 279.2 KB | ||
| 2019-09-19 20:24 |
Abivax gibt Halbjahresergebnisse 2019 und Unternehmens-Update bekannt (News mit…
|
German | HTML • 36.2 KB | ||
| 2019-09-19 20:04 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | PDF • 415.1 KB | ||
| 2019-09-19 20:03 |
Inside Information / News release on accounts, results
|
English | PDF • 537.7 KB | ||
| 2019-09-09 17:45 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 287.1 KB | ||
| 2019-08-19 19:29 |
Inside Information / Other news releases
|
English | PDF • 204.1 KB | ||
| 2019-08-19 19:29 |
Informations privilégiées / Autres communiqués
|
French | PDF • 211.8 KB | ||
| 2019-08-19 18:00 |
Abivax schliet ersten Patienten in klinische Phase-2b-Studie ABX464-103 in der …
|
German | HTML • 25.0 KB | ||
| 2019-08-01 18:44 |
Abivax startet klinische Phase-2a-Studie mit ABX464 gegen rheumatoide Arthritis…
|
German | HTML • 18.8 KB | ||
| 2019-08-01 18:27 |
Inside Information / Other news releases
|
English | PDF • 299.0 KB | ||
| 2019-08-01 18:27 |
Informations privilégiées / Autres communiqués
|
French | PDF • 256.9 KB | ||
| 2019-07-17 18:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 280.9 KB | ||
| 2019-07-17 11:10 |
Franchissement de seuils et déclaration d'intention
|
French | PDF • 267.4 KB | ||
| 2019-07-16 15:27 |
Franchissement de seuil
|
French | PDF • 196.4 KB | ||
| 2019-07-11 22:34 |
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | PDF • 396.2 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
